Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine

被引：18
作者：
Canet, Emmanuel [1 ]
Lerebours, Guy [1 ]
Vilaine, Jean-Paul [2 ]
机构：
[1] Inst Rech Int Servier, F-92415 Courbevoie, France
[2] Inst Rech Servier IdRS, Suresnes, France
来源：
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: WINNERS AND FINALIST CANDIDATES OF THE PRIX GALIEN USA, INTERNATIONAL, AND PRO BONO HUMANITARIAN AWARDS 2010 | 2011年 / 1222卷
关键词：
angina; coronary artery disease; heart failure; heart rate; I(f) inhibition; ivabradine; PLACEBO-CONTROLLED TRIAL; VENTRICULAR SYSTOLIC DYSFUNCTION; CHRONIC STABLE ANGINA; F CURRENT INHIBITOR; DOUBLE-BLIND; MYOCARDIAL-ISCHEMIA; BRADYCARDIAC AGENT; SUBGROUP ANALYSIS; RISK-FACTOR; EFFICACY;
D O I：
10.1111/j.1749-6632.2011.05960.x
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
The link between elevated heart rate and cardiovascular events is established in healthy individuals and in patients with cardiovascular disease. The new agent, ivabradine, specifically and selectively inhibits the I(f) current, with the sole action of heart rate reduction, with no impact on any other cardiac parameters. The benefits of "pure" heart rate reduction with ivabradine have been the focus of one of the largest clinical development programs ever performed, involving >20,000 individuals. Ivabradine has anti-ischemic and antianginal efficacy in monotherapy, as well as in combination with other antianginals, such as beta-blockers, and is safe and well tolerated. Two major morbidity mortality trials, BEAUTIFUL and SHIFT, showed that heart rate reduction with ivabradine dramatically improves prognosis in patients with coronary artery disease and left ventricular dysfunction, symptomatic angina, or chronic heart failure. The development of ivabradine represents a clear innovation in the management of cardiovascular disease.
引用
收藏
页码：90 / 99
页数：10
相关论文
共 42 条
[1]   SUBSETS OF AMBULATORY MYOCARDIAL-ISCHEMIA BASED ON HEART-RATE ACTIVITY - CIRCADIAN DISTRIBUTION AND RESPONSE TO ANTIISCHEMIC MEDICATION [J].
ANDREWS, TC ;
FENTON, T ;
TOYOSAKI, N ;
GLASSER, SP ;
YOUNG, PM ;
MACCALLUM, G ;
GIBSON, RS ;
SHOOK, TL ;
STONE, PH .
CIRCULATION, 1993, 88 (01) :92-100
[2]  
Böhm M, 2010, LANCET, V376, P886, DOI 10.1016/S0140-6736(10)61259-7
[3]   Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells [J].
Bois, P ;
Bescond, J ;
Renaudon, B ;
Lenfant, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (04) :1051-1057
[4]   Characterization of the heart rate-lowering action of ivabradine, a selective If current inhibitor [J].
Borer, Jeffrey S. ;
Le Heuzey, Jean-Yves .
AMERICAN JOURNAL OF THERAPEUTICS, 2008, 15 (05) :461-473
[5]   Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina -: A randomized, double-blind, multicentered, placebo-controlled trial [J].
Borer, JS ;
Fox, K ;
Jaillon, P ;
Lerebours, G .
CIRCULATION, 2003, 107 (06) :817-823
[6]   HOW DOES ADRENALINE ACCELERATE THE HEART [J].
BROWN, HF ;
DIFRANCESCO, D ;
NOBLE, SJ .
NATURE, 1979, 280 (5719) :235-236
[7]   Electrophysiological Effects of a Single Intravenous Administration of Ivabradine (S 16257) in Adult Patients with Normal Baseline Electrophysiology [J].
A. John Camm ;
Chu-Pak Lau .
Drugs in R & D, 2003, 4 (2) :83-89
[8]   Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling [J].
Ceconi, Claudio ;
Comini, Laura ;
Suffredini, Silvia ;
Stillitano, Francesca ;
Bouly, Muriel ;
Cerbai, Elisabetta ;
Mugelli, Alessandro ;
Ferrari, Roberto .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2011, 300 (01) :H366-H373
[9]   Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart [J].
Ceconi, Claudio ;
Cargnoni, Anna ;
Francolini, Gloria ;
Parinello, Giovanni ;
Ferrari, Roberto .
CARDIOVASCULAR RESEARCH, 2009, 84 (01) :72-82
[10]   Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs [J].
Colin, P ;
Ghaleh, B ;
Monnet, X ;
Hittinger, L ;
Berdeaux, A .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (01) :236-240
12345